The investigational oral KRAS G12D inhibitor VS-7375 (GFH375) has shown a promising early safety profile and preliminary ...
The FDA approved darolutamide for mHSPC on June 3, [2025], so we now have this in our armamentarium, along with all the other ...
Results from a phase 1/2 clinical trial (NCT05099172) show the safety and efficacy of sevabertinib (BAY2927088) in patients ...
Vorasidenib significantly improved median progression-free survival and time to next intervention in IDH-mutant grade 2 ...
Community-based CAR T-cell therapy expands access to innovative cancer treatments, improving patient outcomes and reducing ...
Community-based CAR T-cell therapy improves access, reducing travel burdens and hospital admissions for patients with blood ...
Community-based CAR T-cell therapy expands access to innovative cancer treatments, improving patient outcomes and reducing ...
Whole-genome sequencing (WGS) of tumor and germline can generate actionable molecular insights that can guide precision medicine efforts in salivary gland cancer (SGC), according to a new study in JCO ...
A lower number of CD26+ LSCs at diagnosis correlates with optimal molecular response in CML patients at 3, 12, and 24 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback